IceCure says West Cancer Center begins enrollment for ChoICE breast cancer cryoablation study

IceCure Medical announced IRB clearance at West Cancer Center to start the ChoICE post-marketing study of ProSense in low-risk breast cancer.

Patient enrollment is expected in the coming weeks, expanding real-world evidence for a device already cleared for use in women aged 70 and older.

Earlier ICE3 trial results have already been presented, supporting FDA marketing authorization and showing low recurrence with favorable cosmetic satisfaction.

The new study aims to reinforce adoption by validating outcomes in routine practice, supporting commercial uptake in an older patient segment.